⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459968 | 0.97 | — | — | |
| SCHEMBL17812999 | 0.65 | NOS3 (0.48) | — | |
| SCHEMBL2661739 | 0.65 | NOS1 (1.00) | — | |
| SCHEMBL12422425 | 0.65 | NOS3 (0.48) | — | |
| SCHEMBL5560009 | 0.65 | NOS1 (1.00) | — | |
| SCHEMBL24971583 | 0.65 | NOS3 (0.48) | — | |
| SCHEMBL16417238 | 0.65 | NOS3 (0.48) | — | |
| SCHEMBL4195207 | 0.65 | — | — | |
| SCHEMBL5560014 | 0.65 | NOS1 (1.00) | — | |
| SCHEMBL10296536 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723323-B2 | Pharmaceutical use of fused 1,2,4-triazoles | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1615647-B1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | NOVO NORDISK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-7358238-B2 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2008-04-15 | — | — | US | disclosed |
| EP-1785424-A2 | Fused 1,2,4-triazoles and pharmaceutical uses thereof | NOVO NORDISK A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | disclosed |
| EP-1615647-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089380-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| EP-0947510-B1 | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts | BASF AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-0947510-A1 | Process for the preparation of 1,3,4-trisubstituted 1,2,4-triazolium salts | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1992019572-A2 | I-AZA-2-PHENYLHYDRORAZINO-HETEROCYCLES, PROCESS FOR PRODUCING THEM AND PHARMACEUTICALS CONTAINING THEM | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1992-11-12 | — | — | WO | disclosed |
| EP-0111095-B1 | AROMATIC SUBSTITUTED CYCLIC AMIDINES | G.D. Searle & Co. (US) | 1986-12-17 | — | — | EP | disclosed |
| US-4533739-A | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity | G. D. SEARLE & CO. (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0111095-A1 | Aromatic substituted cyclic amidines | G.D. Searle & Co. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4061746-A | Lactamimide inhibitors of gastrointestinal hypersecretion | RICHARDSON-MERRELL INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-3963701-A | DIURETIC, ANTICOAGULANT | RICHARDSON-MERRELL INC. (US) | 1976-06-15 | — | — | US | disclosed |